Request an Appointment

Cancer Answer Line:

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

07-267  Collection of Blood and Tissue from Patients with Upper Aerodigestive Malignancies for Research Purposes (The UAM Tissue Resource) Main Campus  Esophageal, Head & Neck, Lung, Mesothelioma, Thyroid
2559  Genetic and molecular analysis of tumors of the Nervous system and their coverings Main Campus  Brain
3952  Analysis of Human Bone Marrow from Donors Undergoing a Bone Marrow Harvest Main Campus  Aplastic Anemia, Bone Cancer, Bone Marrow Failure, Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML), Leukemia, Chronic Lymphocytic (CLL), Leukemia, Chronic Myeloid (CML), Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin, Multiple Myeloma, Myelodysplastic Syndrome (MDS)
4639  Tissue and Body Fluid Analysis from Renal Cell Cancer Patients Main Campus  Renal
5024  Collection of Blood & Bone Marrow from Normal Volunteers & Patients for Research Purposes (No Funding) Beachwood, Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster  Bone Marrow Failure
7538  Collection of Blood and Bone Marrow Samples of Hematologic Diseases for Research Purposes Main Campus  Multiple Myeloma
A03120114-332 Phase III Trial fo Enzalutamide versus Enzalutamide, Abiraterone and Prednisone for castration resistant metastatic prostate cancer Beachwood, Fairview, Florida Weston, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster Phase 3Prostate
A04120214-353 A RANDOMIZED PHASE III STUDY OF BENDAMUSTINE PLUS RITUXIMAB VERSUS IBRUTINIB PLUS RITUXIMAB VERSUS IBRUTINIB ALONE IN UNTREATED OLDER PATIENTS (≥ 65 YEARS OF AGE) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Beachwood, Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, Parma, South Pointe, Strongsville, Wooster Phase 3Leukemia, Chronic Lymphocytic (CLL)
ABBV 191313-1173 A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion Main Campus Phase 2Leukemia, Chronic Lymphocytic (CLL)
ABTC 120213-927 Phase I Study of MK-1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma Main Campus Phase 1Brain, Glioblastoma
ACE 1A14 14-762 A Phase 1b/2 multi-center, open label, dose- escalation study to determine the maximum tolerated dose, safety, and efficacy of acy-1215 (ricolinostat) in combination with pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma Main Campus Phase 1, Phase 2Multiple Myeloma
ACLN 181213-173 A Phase 2 Randomized Study of Dalantercept in Combination Main Campus  Renal
AGSP 1Z14 15-124 A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation Main Campus Phase 1Hematologic Malignancy, Leukemia, Acute Myeloid (AML), Myelodysplastic Syndrome (MDS)
ALEX 1Z1111-245 Paroxysmal Hemoglobinuria Registry Main Campus  PNH
ANG 111414-1095 A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients with Recurrent Brain Metastases Main Campus Phase 2Brain, Breast
ARRY 16231113-1209 The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum (ARRAY BioPharma Inc.) Fairview, Hillcrest, Main Campus  Gynecologic
ARRY 1A1314-258 A Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients With Advanced Multiple Myeloma Main Campus Phase 2Multiple Myeloma
ARRY 1A14 14-1209 A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma Main Campus Phase 2Multiple Myeloma
ASTX 151212-974 A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC) Main Campus  Lung
BAX 1Z1414-375 Phase 3b Continuation Study of the Safety and Efficacy of Prophylactic BAX 855 in PTPs with Severe Hemophilia A Main Campus Phase 3Hemophilia A

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2015 Cleveland Clinic. All rights reserved.